HGCSG 1301: A multicenter, double-blind, randomized controlled phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer treated with IRIS/Bev as second-line therapy—Updated analysis of antitumor efficacy.

Atsushi Ishiguro,Hiroshi Nakatsumi,Tetsuhito Muranaka,Yasuyuki Kawamoto,Satoshi Yuki,Miki Tateyama,Atsushi Sato,Takuto Miyagishima,Michio Nakamura,Masayoshi Dazai,Hiroyuki Okuda,Yasuo Takahashi,Tomoe Kobayashi,Takashi Kato,Kazuteru Hatanaka,Toraji Amano,Yuh Sakata,Yoshito Komatsu

HGCSG 1301: A multicenter, double-blind, randomized controlled phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer treated with IRIS/Bev as second-line therapy—Updated analysis of antitumor efficacy.

2020

Atsushi Ishiguro
Hiroshi Nakatsumi
Tetsuhito Muranaka
Yasuyuki Kawamoto
Satoshi Yuki
Miki Tateyama
Atsushi Sato
Takuto Miyagishima
Michio Nakamura
Masayoshi Dazai
Hiroyuki Okuda
Yasuo Takahashi
Tomoe Kobayashi
Takashi Kato
Kazuteru Hatanaka
Toraji Amano
Yuh Sakata
Yoshito Komatsu

108Background: IRIS (irinotecan plus S-1) plus bevacizumab (IRIS/Bev) is one of the standard chemotherapies in Japan for metastatic colorectal cancer (mCRC) as the first-line or second-line therapy...

Keywords:

Second-line therapy
Gastroenterology
double blind
Internal medicine
Placebo
Colorectal cancer
Medicine
Physical therapy
Diarrhea
in patient
Bevacizumab
Irinotecan
Oncology
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations